CASP6 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 769-P renal epithelial adenocarcinoma cell line. This product features targeted disruption of the CASP6 gene, encoding the executioner caspase-6, via CRISPR/Cas9-mediated gene editing. The polyclonal population consists of a heterogeneous mix of cells with stable loss-of-function mutations, eliminating caspase-6 expression. It serves as a robust tool for studying caspase-6-dependent pathways without single-cell cloning, preserving genetic diversity while ensuring knockout across the culture.
The parental 769-P cell line originates from a primary clear cell adenocarcinoma of the kidney in a 63-year-old female and is a widely used model for clear cell renal cell carcinoma (ccRCC). 769-P cells retain key features of renal cancer, including aberrant signaling, and are suitable for studying tumor biology and drug responses. The epithelial adherent cells facilitate in vitro assays, and the CASP6 knockout enables dissection of caspase-6 contributions specifically in ccRCC pathogenesis.
Caspase-6 is an executioner caspase activated downstream of death receptors (FAS, TNFR1) and the apoptosome (cytochrome c/Apaf-1/caspase-9). Its activation is regulated by caspase-8, p53, and KLF10, and it cleaves critical substrates such as lamin A/C, PARP1, cytokeratin 18, and ??-tubulin to execute apoptosis. Caspase-6 activity is inhibited by XIAP, BIRC5/Survivin, ARC, and FLIP. It also processes caspase-8 and participates in inflammatory cytokine maturation. Disruption of CASP6 abrogates substrate cleavage and attenuates both intrinsic and extrinsic apoptotic signaling, while potentially altering inflammatory responses.
In 769-P ccRCC cells, CASP6 knockout confers resistance to apoptotic stimuli, including chemotherapeutics and death receptor ligands, modeling a drug resistance mechanism. By comparing parental cells with the knockout population, researchers can identify caspase-6-specific pathways in ccRCC progression and therapy response. This model is particularly useful for investigating apoptosis-proliferation crosstalk and screening compounds that bypass caspase-6-dependent cell death, as well as for studying the impact of apoptosis deficiency on the tumor microenvironment.
These polyclonal CASP6 knockout 769-P cells support diverse applications: western blotting and caspase activity assays to monitor substrate cleavage; Annexin V flow cytometry and TUNEL assays for apoptosis quantification; RT-qPCR and RNA-seq for transcriptomic profiling; cell viability assays for drug resistance screening; and cytokine ELISA for inflammatory signaling studies. For further technical information or custom validation inquiries, please contact Ascent Research.
